G Denapiene

Clinic of Gastroenterology, Nephrourology and Surgery, Medical Faculty of Vilnius University, Vilnius University, Vilnius, Lithuania.

4 publications 2011 – 2016
Polymorphism, Single NucleotideGenetic Predisposition to DiseaseCase-Control StudiesGenome-Wide Association StudyColitis, Ulcerative

What does G Denapiene research?

G Denapiene studies ulcerative colitis, a chronic condition that causes inflammation in the digestive tract. They specifically explore how propionyl-L-carnitine, a compound that may help with energy metabolism, affects patients already receiving stable treatment for this condition. By examining how this therapy can improve patient responses, they aim to find better ways to manage symptoms and enhance the quality of life for those suffering from ulcerative colitis.

Key findings

  • 72% of patients taking propionyl-L-carnitine experienced a positive response to treatment, compared to 50% of those receiving a placebo.
  • The treatment was generally safe, with side effects primarily related to the stomach.
  • The study highlights the potential for propionyl-L-carnitine to be an effective addition to existing ulcerative colitis therapies.

Frequently asked questions

Does Dr. Denapiene study ulcerative colitis?
Yes, Dr. Denapiene specifically researches ulcerative colitis and ways to improve treatment options for this condition.
What treatments has Dr. Denapiene researched?
Dr. Denapiene has researched the use of propionyl-L-carnitine therapy in patients with ulcerative colitis.
Is Dr. Denapiene's work relevant to patients with ulcerative colitis?
Absolutely, their research focuses on enhancing management strategies for individuals living with ulcerative colitis.

Publications in plain English

TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.

2016

Advances in medical sciences

Steponaitiene R, Kupcinskas J, Survilaite S, Varkalaite G, Jonaitis L +5 more

Plain English
This study examined how certain genetic variations in Lithuanian patients with inflammatory bowel disease (IBD) affect their responses to the medication azathioprine (AZA), particularly in terms of side effects. Among 551 patients, it was found that 11% experienced a serious drop in blood cell counts (myelotoxicity) due to AZA, and those with specific TPMT genetic variants were more likely to experience this issue. The findings highlight the importance of genetic testing to help predict who may suffer from harmful side effects when taking AZA, ultimately improving treatment safety. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

PubMed

Replication study of ulcerative colitis risk loci in a Lithuanian-Latvian case-control sample.

2013

Inflammatory bowel diseases

Skieceviciene J, Kiudelis G, Ellinghaus E, Balschun T, Jonaitis LV +15 more

Plain English
This study looked at the genetic factors that influence ulcerative colitis (UC) in patients from Lithuania and Latvia. Researchers examined 77 genetic markers and found that 14 of them were linked to an increased risk of UC, highlighting specific gene locations such as the HLA region and PTPN22. Understanding these genetic connections helps identify who is at greater risk for this disease, which can lead to better prevention and treatment strategies. Who this helps: Patients with ulcerative colitis and their doctors benefit from this research.

PubMed

Assessment of heterogeneity between European Populations: a Baltic and Danish replication case-control study of SNPs from a recent European ulcerative colitis genome wide association study.

2011

BMC medical genetics

Andersen V, Ernst A, Sventoraityte J, Kupcinskas L, Jacobsen BA +7 more

Plain English
This study looked at the genetic factors that might influence ulcerative colitis (UC) in Nordic countries compared to the rest of Europe. Researchers found that a specific genetic variant, rs5771069, was linked to UC in a combined group of patients from Denmark, the Baltic region, and Norway, showing a risk pattern influenced mainly by the Norwegian sample (with a statistical significance value of P = 0.02). However, other tested genetic variants, including rs7809799, did not show significant associations, highlighting differences in genetic risk between populations. Who this helps: This research benefits patients with ulcerative colitis by improving understanding of how genetics may differ across regions.

PubMed

Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.

2011

Alimentary pharmacology & therapeutics

Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG +15 more

Plain English
In this study, researchers looked at the effects of propionyl-L-carnitine (PLC) on patients with mild-to-moderate ulcerative colitis (UC) who were already stable on treatment. They found that 72% of patients taking PLC had a positive response to treatment, compared to 50% in the placebo group, showing that PLC may help improve symptoms. The treatment was generally safe, with side effects mostly related to the stomach. Who this helps: This helps patients with ulcerative colitis looking for better management options.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.